Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidationand TNFa Release - St. Clair Scope

Pharmacology, Toxicology and Pharmaceutical Science

1. Doxorubicin 100%
2. Coenzyme M 100%
3. Plasma Protein 100%
4. Tumor Necrosis Factor 23%
5. Anthracycline 23%
6. Chemotherapy Regimens 15%
7. Cardiotoxicity 7%
8. Ifosfamide 7%
9. Metronidazole 7%
10. Cancer Chemotherapy 7%
11. Alkylating Agent 7%
12. Malignant Neoplasm 7%
13. Nonhodgkin Lymphoma 7%
14. Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine 7%
15. Cystitis 7%
16. Heart Injury 7%
17. Breast Cancer 7%
18. Clinical Study 7%
19. Clinical Trial 7%
20. Drug Interaction 7%
21. Antioxidant 7%
22. Myocardial Disease 7%